Alzheimer's disease (AD) is the most common age-related neurodegenerative disease, and the disease mechanism is complex and remains poorly understood. AD is the leading cause of dementia and represents a major clinical challenge. Therefore, early detection and disease-modifying therapeutics are urgently needed. Piezo1 is a mechanically activated Ca2+-permeable cation channel with a key role in mechanosensing and mechano-transduction (). Recent studies have disclosed a critical role for the Piezo1 channel in modifying AD and, in addition, a positive association of the Piezo1 channel activity in red blood cells (RBCs) with the early development of AD-related dementia. In this opinion piece, we summarize the recent findings and debate whether the Piezo1 channel is a feasible target for formulating strategies for modifying AD and detecting AD-related dementia at the early stage.
Microglial Piezo1 channel activation by fAβ inhibits AD via stimulating microglial phagocytosis of Aβ
Accumulation of amyloid β peptides (Aβ) not only leads to the formation of extracellular senile plaques, one of the pathohistological hallmarks of AD but also acts as an early disease-driving factor. The capacity of microglia to phagocytose Aβ is severely impaired in AD, which plays a critical part in Aβ accumulation and plaque formation. In the plaques, Aβ exists in diverse species, including fibrillar Aβ (fAβ) that significantly stiffens the plaques and surrounding tissues. Interestingly, the Piezo1 channel expression was upregulated in 5xFAD mice, a mouse model of Aβ-driven AD, specifically in a plaque-associated subpopulation of microglia (). Consistently, the Piezo1 channel expression was also increased in mouse microglia cultured on fAβ. More importantly, exposure to fAβ induced Ca2+ influx via activating the Piezo1 channel () and, in contrast, the Ca2+ response in microglia evoked by the Piezo1 channel activator Yoda1 was inhibited by pre-treatment with soluble Aβ (), indicating Aβ species-dependent modulation of the Piezo1 channel. Activation of the Piezo1 channel using Yoda1 stimulated microglial migration and Aβ phagocytosis (). As further demonstrated in 5xFAD mice, intraperitoneal injection of Yoda1-enhanced microglial migration and clustering around the plaques and Aβ phagocytosis, alleviated Aβ accumulation and plaque formation and, most importantly, improved cognitive function, whereas deletion of microglial Piezo1 channel expression impaired microglial clustering around the plaques and Aβ internalization, leading to heightened Aβ accumulation and plaque formation and accelerated synaptic and cognitive deficits (; ). Collectively, these observations provide consistent evidence to indicate that the activation of the microglial Piezo1 channel by fAβ-enriching plaques instigates microglial migration and Aβ phagocytosis, hence limiting Aβ accumulation and plaque formation and improving cognitive function. In other words, the microglial Piezo1 channel plays a vital role in inhibiting AD progression (Figure 1).
Figure 1
Piezo1 channel activation dampens the proinflammatory response of microglia and astrocytes to Aβ/LPS
In addition to the impaired clearance of Aβ by microglial phagocytosis, chronic and low-grade inflammation, mediated by microglia and also astrocytes, is well recognized as a vital factor in AD progression (). Emerging evidence points to the glial Piezo1 channels for their role in regulating the proinflammatory response of glial cells to Aβ or lipopolysaccharide (LPS), a neurotoxin released by Gram-negative bacteria. As shown in cultured microglia, exposure to stiff Aβ induced activation of the Piezo1 channel, and thereby promoted microglial generation of reactive oxygen species (ROS) that in turn impaired microglial viability and the capacity of phagocytosis, favoring an important role of microglial Piezo1 channel in the intricate interplays between neuroinflammation and Aβ phagocytosis (). The Piezo1 channel expression was upregulated in TgF344-AD rat brains, mostly noticeable in reactive astrocytes surrounding the plaques in aged TgF344-AD rats infected with Escherichia coli (). As shown in cultured astrocytes, the Piezo1 channel expression was upregulated by Aβ-conditioned microglial media, indicating the requirement of microglia in upregulating the astrocytic Piezo1 channel expression (). LPS-evoked proinflammatory response of astrocytes was inhibited by Piezo1 channel activation (). Similarly, LPS-evoked proinflammatory response of microglia, or specifically generation of proinflammatory cytokines, tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6, was inhibited by Piezo1 channel activation (). In microglia, such an inhibition was shown to be mediated by Piezo1-mediated Ca2+ influx-dependent suppression of LPS-induced toll-like receptor 4 (TLR4)-mediated activation of the NF-kB signaling pathway (). In short, Piezo1 channel activation dampens the proinflammatory response of microglia (Figure 1) and astrocytes to exposure to Aβ/LPS, but the contribution of these Piezo1-mediated inhibitory mechanisms in AD merits further investigations. Nevertheless, these findings provide more information to endorse and expand the inhibitory role of the Piezo1 channel in AD progression.
Microglial Piezo1 channel activation by LPS of gut bacterial origin promotes C1q/C3-mediated synaptic pruning and facilitates AD progression
Activation of the microglial complement pathways promotes synaptic pruning, which is a well-recognized mechanism for synaptic loss in the early stage of AD (). LPS-containing extracellular vesicles (EVs) released or originated from gut bacteria were detected at a higher level in AD patients than in healthy individuals (). LPS-containing EVs isolated from human blood (bEVs), upon injection into mice peripherally, penetrated the blood–brain barrier (BBB) and emerged in the brain. Moreover, LPS from such bEVs sufficiently stimulated the microglial C1q-C3 complement pathway to induce synaptic pruning in mice, which was alleviated by depleting microglial Piezo1 channel expression. These observations support the notion that activation of the microglial Piezo1 channel mediates synaptic loss by EV-carried LPS from gut bacteria to the brain (Figure 1). Such a finding sheds novel mechanistic light on the gut–brain axis hypothesis of AD. However, how LPS induces Piezo1 channel activation remains unclear, and evidence for its significance in AD still awaits. It is important to notice that activation of such a microglial Piezo1 channel mechanism facilitates AD progression and thus is opposite to those described above.
RBC Piezo1 channel activity emerges as a diagnostic indicator for the early detection of AD-related dementia
In addition to the role in modifying AD, emerging evidence suggests an increase in the Piezo1 channel activity in RBCs and supports a positive association of such increased Piezo1 channel activity with the early development of AD-related dementia (). The activity of the Piezo1 channel expressed in RBCs exerts important influences on the volume, shape, and deformability of RBCs, or the ability of RBCs in microcirculation in the brain. Aβ are accumulated in blood vessels and interact with RBCs and, by inducing RBC aggregation, impede microcirculation, leading to cerebral amyloid angiopathy. Pre-incubation of RBCs from healthy donors with Aβ decreased plasma membrane stiffness and viscosity, resulting in higher pressure needed for Piezo1 channel activation (). Acute pre-incubation with Aβ attenuated Piezo1 channel activation, indicating an inhibitory effect on the Piezo1 channel in RBCs (), similar to what was described above for the effect of soluble Aβ on microglia (). Exposure to Yoda1 induced similar Ca2+ responses in RBCs from both mild cognitive impairment (MCI) and AD patients, which, however, were significantly higher than those in RBCs from healthy subjects. Yoda1-induced cell shrinkage and reduction in the cell size were also greater in RBCs from MCI patients as well as AD patients, as compared to those in healthy RBCs, indicating that upregulation of the Piezo1 expression occurs in MCI or the early stage of AD. Furthermore, interaction analysis, evaluating Piezo1-mediated Ca2+ flux in RBCs, conventional AD biomarkers, classification of patients, memory scores, and magnetic resonance imaging (MRI) measurements, revealed positive association of the increase in the Piezo1 channel activity in RBCs with early AD-related dementia, leading to the proposal of incorporating the assessment of the RBC Piezo1 channel activity in diagnostic tests of AD is instructive in the early detection of AD-related dementia ().
In summary, recent studies have disclosed an important role for the mechanosensitive Piezo1 channel in glial cells, particularly microglia, in modifying AD via distinctive mechanisms and, in addition, positive association of an increase in RBC Piezo1 channel activity with early development of AD-related dementia. The findings offer novel mechanistic insights into AD. However, further research is anticipated to gain a better understanding of the Piezo1 channel mechanism of AD and more information to inform whether the Piezo1 channel can be used as a feasible target for formulating strategies to modify AD and detect AD-related dementia at an early stage.
Statements
Author contributions
MZ: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Validation, Visualization, Writing – original draft, Writing – review & editing. HH: Conceptualization, Data curation, Formal analysis, Investigation, Validation, Visualization, Writing – original draft, Methodology, Writing – review & editing. HL: Data curation, Formal analysis, Investigation, Validation, Visualization, Writing – original draft. XB: Data curation, Formal analysis, Validation, Investigation, Writing – original draft. HS: Data curation, Formal analysis, Funding acquisition, Validation, Investigation, Writing – original draft. LW: Data curation, Formal analysis, Supervision, Validation, Investigation, Writing – original draft. L-HJ: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing.
Funding
The author(s) declare that financial support was received for the research and/or publication of this article. This study was funded by the Alzheimer's Research Trust (ART/PPG2009A/2) and Henan Medical University to L-HJ, Key Research Project Plan for Higher Education Institutions of Henan Province (23A310001) and Henan Province Science and Technology Research Project (242102310333) to MZ, Key Science and Technology Project of Henan Province (232102310046) to HS, and Henan College Student Innovation and Entrepreneurship Training Program (202410472046) to XB and HH.
Acknowledgments
Visiting Professorship from the University of Tours to L-HJ.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Gen AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
HenekaM. T.van der FlierW. M.JessenF.HoozemannsJ.ThalD. R.BocheD.et al. (2025). Neuroinflammation in Alzheimer disease. Nat. Rev. Immunol. 25, 321–352. doi: 10.1038/s41577-024-01104-7
2
HuJ.ChenQ.ZhuH.HouL.LiuW.YangQ.et al. (2023). Microglial piezo1 senses abeta fibril stiffness to restrict alzheimer's disease. Neuron111, 15–29.e8. doi: 10.1016/j.neuron.2022.10.021
3
JänttiH.SitnikovaV.IshchenkoY.ShakirzyanovaA.GiudiceL.UgidosI. F.et al. (2022). Microglial amyloid beta clearance is driven by piezo1 channels. J. Neuroinflammation19:147. doi: 10.1186/s12974-022-02486-y
4
LiuY.ZhangJ.ZhaoY.FangF.ZhangS.AnQ.et al. (2025). Mechanotransduction activates microglia and impairs phagocytosis in stiff amyloid-β plaques. Adv. Sci. 23:e03389. doi: 10.1002/advs.202503389
5
MalkoP.JiaX.WoodI.JiangL. H. (2023). Piezo1 channel-mediated Ca2+ signaling inhibits lipopolysaccharide-induced activation of the NF-κB inflammatory signaling pathway and generation of TNF-α and IL-6 in microglial cells. Glia71, 848–865. doi: 10.1002/glia.24311
6
SitnikovaV.NurkhametovaD.BraidottiN.CiubotaruC. D.GiudiceL.ImpolaU.et al. (2025). Increased activity of Piezo1 channel in red blood cells is associated with Alzheimer's disease-related dementia. Alzheimers Dement. 21:e70368. doi: 10.1002/alz.70368
7
TennerA. J.PetriskoT. J. (2025). Knowing the enemy: strategic targeting of complement to treat Alzheimer disease. Nat. Rev. Neurol. 21, 250–264. doi: 10.1038/s41582-025-01073-y
8
Velasco-EstevezM.RolleS. O.MampayM.DevK. K.SheridanG. K. (2020). Piezo1 regulates calcium oscillations and cytokine release from astrocytes. Glia68, 145–160. doi: 10.1002/glia.23709
9
XiaoB. (2024). Mechanisms of mechanotransduction and physiological roles of piezo channels. Nat. Rev. Mol. Cell. Biol. 25, 886–903. doi: 10.1038/s41580-024-00773-5
10
ZhaoX.YuJ.XuB.XuZ.LeiX.HanS.et al. (2025). Gut-derived bacterial vesicles carrying lipopolysaccharide promote microglia-mediated synaptic pruning. Alzheimers Dement. 21:e70331. doi: 10.1002/alz.70331
Summary
Keywords
Piezo1, Alzheimer's disease, microglia, phagocytosis, synaptic pruning
Citation
Zhang M, Hou H, Li H, Bai X, Song H, Wang L and Jiang L-H (2025) The mechanosensitive Piezo1 channel mechanism of Alzheimer's disease and implications for the development of therapeutic or early detection strategies. Front. Aging Neurosci. 17:1707659. doi: 10.3389/fnagi.2025.1707659
Received
17 September 2025
Revised
03 November 2025
Accepted
17 November 2025
Published
03 December 2025
Volume
17 - 2025
Edited by
Marco Bisaglia, University of Padua, Italy
Reviewed by
Van Thi Ai Tran, Sungkyunkwan University, Republic of Korea
Updates
Copyright
© 2025 Zhang, Hou, Li, Bai, Song, Wang and Jiang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Lin-Hua Jiang, l.h.jiang@leeds.ac.uk; jianglinhua@xxmu.edu.cn
† These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.